Aardvark Therapeutics, Inc.
AARD Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$1.39
KIRA · Stoqly’s AI analyst, in plain words
- Aardvark Therapeutics, Inc. had $0.0M of revenue in fiscal 2025.
- Aardvark Therapeutics, Inc. lost $57.6M in fiscal 2025.
- Free cash flow was −$54.3M in fiscal 2025, — of revenue.
Market cap
$30.4M
P/E
—
Revenue
$0.0M
Net income
−$57.6M
Free cash flow
−$54.3M
Operating margin
—
Aardvark Therapeutics, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$57.6M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Aardvark Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 23, 2026
- Legal name
- Aardvark Therapeutics, Inc.
- CIK
- 0001774857
Aardvark Therapeutics, Inc. · AARD
Results and finances
The last 2 fiscal years. Amounts in USD.
| Fiscal year | FY24 | FY25 |
|---|---|---|
| Sales and profit | ||
| Revenue | — | $0.0M |
| Net income | −$20.6M | −$57.6M |
| Diluted EPS | −$5.15 | −$2.93 |
| Cash | ||
| Cash from operations | −$18.1M | −$54.2M |
| Capital expenditure | $0.1M | $0.1M |
| Free cash flow | −$18.2M | −$54.3M |
| Share count change | — | 391.1% |
| Debt and strength | ||
| Cash and short-term investments | $73.7M | $110M |
| Shareholders' equity | −$54.6M | $107M |
| Current ratio | 15.0x | 10.6x |
| Returns and quality | ||
| Return on equity | — | −221.5% |
| Return on tangible equity | — | −54.0% |
| Altman Z'' | −9.2 | 9.5 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.4M
1 insider
Of sales under plans
100%
$0.4M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Aardvark Therapeutics, Inc. · AARD
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.39 a share, the company is worth $30.4M.
Source: SEC EDGAR XBRL filings (CIK 0001774857). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.